Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
LONDON - Ceiba Investments Limited (LSE:CBA) announced the appointment of three new independent non-executive directors effective July 3, 2025, according to a press release issued Friday.
The new board members are Dena Bellamy, Mary Dunphy, and Robin Smith. All three will serve on the company’s Audit Committee, Nomination Committee, and Management Engagement Committee.
Bellamy brings over 25 years of investment banking experience, having worked at institutions including Rothschild, Merrill Lynch, and Commerzbank (ETR:CBKG). She previously held a board position at Biofarma Innovations, a joint venture with Cuban state-owned pharmaceutical company BioCubaFarma.
Dunphy, a law graduate from Trinity College, has chaired two Nasdaq-listed companies and was previously a Global Equity Partner at Accenture (NYSE:ACN) and Teneo. She also served as Global CEO of CoderDojo, a charity operating in 65 countries.
Smith, a Fellow of the Chartered Association of Certified Accountants, worked in senior positions with three fiduciary groups from 1984 until 2024. Most recently, he served as Managing Director of the Praxis Guernsey Fiduciary business until his retirement in February 2024.
The appointments follow the retirement of Keith Corbin, who previously served as Senior Independent (LON:IOG) Director and left the board at the company’s Annual General Meeting on July 3. Ceiba stated that a successor for the Senior Independent Director role will be announced later.
John Herring, Chairman of Ceiba Investments, said in the statement: "We are extremely pleased to welcome Dena, Mary and Robin on to the Board. Each of them brings significant skills, knowledge and a fresh perspective to the Board."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.